Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

Part of paid clinical trials in Los Angeles, California.

Sponsor
European Foundation for Study of Chronic Liver Failure
Study ID
NCT04613921
Status
Recruiting

Conditions

  • Acute-On-Chronic Liver Failure
  • Liver Cirrhosis
  • Liver Diseases
  • Liver Transplant; Complications

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Observational Protocol — OTHER
    The cohorts will be followed for one year after LT transplantation except for group 3 (1-year follow-up after inclusion)

Study Details

Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.

Key Dates

Start date
Jul 8, 2021
Status verified
Oct 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
3,000 participants (estimated)

Arms

  • Arm: Group 1
    patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list (n=2,000)
  • Arm: Group 2
    patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD \> 20) at the time of listing (n=500)
  • Arm: Group 3
    patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation (n=500)

Primary Outcome Measure

Survival [ Time Frame: 1 year ]

Central Contacts

Locations (18)

FacilityCityStateZIPSite coordinators
Cedars-Sinai Comprehensive Transplant CenterLos AngelesCalifornia90048
Alexander Kuo
Alexander Kuo (PRINCIPAL_INVESTIGATOR)
Nicholas Nissen (SUB_INVESTIGATOR)
University of ColoradoAuroraColorado80045
Michael Kriss
303-724-1030
Michael Kriss (PRINCIPAL_INVESTIGATOR)
Elizabeth Pomfret (PRINCIPAL_INVESTIGATOR)
Tampa General HospitalTampaFlorida33606
Nyingi Kemmer
Ningi Kemmer (PRINCIPAL_INVESTIGATOR)
Piedmont HealthcareAtlantaGeorgia30309
Lance Stein (PRINCIPAL_INVESTIGATOR)
Marwin Kazimi (SUB_INVESTIGATOR)
Northwestern Memorial HospitalChicagoIllinois60611
Justin R Boike
+1 312-926-2000
Justin R Boike (PRINCIPAL_INVESTIGATOR)
Andrés Duarte (SUB_INVESTIGATOR)
The University of Chicago MedicineChicagoIllinois60637
University of Maryland School of MedicineBaltimoreMaryland21201
Kirti Shetty
410 3281328
Kirti Shetty (PRINCIPAL_INVESTIGATOR)
John Lamattina (SUB_INVESTIGATOR)
Icahn School of Medicine at Mount SinaiNew YorkNew York10029-5674
Ghideon Ezaz
Ghideon Ezaz (PRINCIPAL_INVESTIGATOR)
Chiara Rocha (SUB_INVESTIGATOR)
Montefiore Medical CenterNew YorkNew York10467
Brett Fortune
+1 718-920-4321
Brett Fortune (PRINCIPAL_INVESTIGATOR)
Milan Kinkhabwala (SUB_INVESTIGATOR)
Weill Cornell MedicineNew YorkNew York10021
Russell Rosenblatt
646-962-5483
Russell Rosenblatt (PRINCIPAL_INVESTIGATOR)
Ben Samstein (SUB_INVESTIGATOR)
University of CincinnatiCincinnatiOhio45219-
Cleveland ClinicClevelandOhio44195
Bijan Eghtesad
Bijan Eghtesad (PRINCIPAL_INVESTIGATOR)
Christina Lindenmeyer (PRINCIPAL_INVESTIGATOR)
University of PennsylvaniaPhiladelphiaPennsylvania19104-
Vanderbilt University Medical CenterNashvilleTennessee37232
Manhal Izzy
+1 615-322-5000
Manhal Izzy (PRINCIPAL_INVESTIGATOR)
Baylor College of Medicine (Scott & White)DallasTexas75246
Amar Gupta (PRINCIPAL_INVESTIGATOR)
Robert Rahimi (PRINCIPAL_INVESTIGATOR)
Baylor St. Luke's Medical CentreHoustonTexas77030
Jalal Prasun
Jalal Prasun (PRINCIPAL_INVESTIGATOR)
Michael E DeBakey VA Medical CenterHoustonTexas77030-4211
Rubén Hernáez
Rubén Hernáez (PRINCIPAL_INVESTIGATOR)
University of Utah HealthSalt Lake CityUtah84132
Juan Gallegos-Orozco
801.581.7878
Juan Gallego-Orozco (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

Related Studies